This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Christmas disease크리스마스병 (크리스마스인자결핍증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D67 (hereditary factor IX deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsChristmas disease, hemophilia B, hereditary factor IX deficiency, plasma thromboplastin component deficiency (PTC deficiency), Congenital factor IX deficiency
C. Adult onsetPossibility of first onset in adulthood: not low — not a few patients with mild disease (FIX:C 5–40%) remain asymptomatic until surgery or trauma and are first diagnosed in adulthood; in particular, patients with the FIX Leyden variant show a unique course in which disease that is severe in childhood improves spontaneously after puberty and is diagnosed as mild in adulthood.
1. HistoryThe name "Christmas disease" derives not from the holiday but from the surname of the first identified patient, Stephen Christmas, and it was first reported as a new type of hemophilia in a 1952 BMJ paper.
2. CausesCaused by reduced FIX activity or quantity due to various variants (point mutations about 84%, deletions, insertions, frameshifts, etc.) in the F9 gene located on the long arm of the X chromosome at Xq27.1.
3. GeneticsX-linked recessive. F9 gene 34 kb, 8 exons, 415 aa, 55 kDa. Gla-EGF1-EGF2-AP-SP domains. Characteristic Leyden variant (AHRE damage, recovery after puberty) and Padua variant (used in gene therapy).
4. Epidemiology1 in 25,000–30,000 males. 160,000 people affected worldwide. About 750 type B patients in KBDR. Inhibitor incidence 3–5%.
5. PathophysiologyFIXa + FVIIIa + Ca²⁺ + phospholipid = intrinsic tenase complex → FX activation → thrombin generation. In FIX deficiency this complex cannot form → hemostatic failure.
6. SymptomsSevere: spontaneous hemarthrosis and muscle hematomas. Moderate: excessive bleeding after trauma. Mild: delayed hemostasis after surgery or tooth extraction. Leyden type: severe in childhood → mild in adulthood.
7. SignsProlonged APTT, reduced FIX:C, normal PT, low inhibitor rate (3–5%). Anaphylaxis may accompany inhibitor development.
8. ScreeningFIX:C in newborns with a family history (neonatal normal values are low, so retest after 6 months). F9 gene analysis. Measure FIX:C if APTT is prolonged.
9. DiagnosisAPTT → FIX:C (one-stage/chromogenic) → mixing test → inhibitor testing → F9 gene analysis. Promoter region analysis if Leyden is suspected.
10. TreatmentFIX concentrates (standard/EHL), emicizumab, fitusiran, gene therapy (etranacogene dezaparvovec). Inhibitor management: emicizumab preferred; ITI has poor efficacy.
11. PrognosisNormal life expectancy. Low inhibitor incidence (3–5%). Long-term efficacy of gene therapy under observation.
12. PreventionGenetic counseling, F9 testing of carriers, prenatal diagnosis (CVS/amniocentesis), PGT, early prophylaxis.
13. ReferencesBiggs R et al. Christmas disease: a condition previously mistaken for haemophilia. BMJ. 1952 … and 9 other papers

1. History

Origin of the name "Christmas disease"

The name "Christmas disease" has nothing to do with the Christmas holiday. It derives directly from the surname of the patient whose case led to the disease first being recognized as a distinct entity, Stephen Christmas. Stephen Christmas was a boy born in Canada in 1947 who, because of an abnormal bleeding tendency from early childhood, was examined at a hospital in the Oxfordshire area near London, England. At the time he was presumed to have hemophilia, but when the research team in charge performed detailed tests, they observed that the clotting time of his plasma was corrected when mixed with plasma from patients with existing hemophilia (later classified as hemophilia A). This meant that Stephen Christmas had a disease caused by a separate clotting factor deficiency, different from the hemophilia known until then.

Pavlovsky's pioneering observation in 1947

Behind the discovery of Christmas disease was an important observation made in 1947 by Alfredo Pavlovsky of Argentina. Pavlovsky experimentally confirmed that mixing the plasma of two different hemophilia patients corrected the clotting time. This observation was the first experimental evidence suggesting that hemophilia could result from deficiencies of at least two different clotting factors. Pavlovsky himself did not fully systematize the clinical significance of this result, but the observation laid the groundwork for the systematic study by the Oxford research team in England five years later.

The 1952 BMJ paper and the first report of the disease

On December 27, 1952, a paper titled "Christmas disease: a condition previously mistaken for haemophilia", co-authored by seven authors including Rosemary Biggs, A.S. Douglas, R.G. Macfarlane, J.V. Dacie, W.R. Pitney, C. Merskey and J.R. O'Brien, was published in the British Medical Journal. In this paper, the authors demonstrated, in a series of patients including Stephen Christmas, the existence of a new type of coagulation disorder distinct from the hemophilia known at the time (factor VIII deficiency, hemophilia A). The key experiment was that the patients' plasma and the plasma of existing hemophilia patients mutually corrected clotting function when mixed, which for the first time clearly established that the two diseases were due to different deficient factors. The disease was named "Christmas disease" after the surname of the first identified patient, Stephen Christmas, and because the paper was published in December, coinciding with the Christmas holiday, the name became all the more widely remembered. In the same year and in the same journal, Aggeler et al. in the United States independently named a similar deficient factor PTC (Plasma Thromboplastin Component) and reported it almost simultaneously.

The life and tragic end of Stephen Christmas

The life of Stephen Christmas himself symbolizes a tragic aspect of 20th-century hemophilia history. He later returned to Canada, grew up there and lived with hemophilia B all his life. Because the plasma-derived concentrates used to treat hemophilia in the 1970s–80s (especially cryoprecipitate and FVIII/FIX concentrates) were manufactured by pooling the plasma of large numbers of donors, contaminated blood products containing HIV or HCV were widely administered to hemophilia patients around the world. In Canada, this led to the so-called "Tainted blood scandal," a tragedy in which thousands of hemophilia patients and transfusion recipients were infected en masse with HIV and HCV. Stephen Christmas was also infected with HIV in this process and died of AIDS complications on December 20, 1993, at the age of 41. The paradox that the person who became the reference point of the disease bearing his name died of an adverse effect of treatment for that disease is recorded in the history of hematology as a case that symbolically demonstrates the importance of blood safety systems.

Naming of factor IX and scientific progress

In the same year, 1952, Schulman and Smith named this newly discovered clotting factor "factor IX (FIX)," and this name came into international use. Later, in 1964, when the coagulation cascade model was proposed by Macfarlane, Davie and Ratnoff, the precise position and role of FIX in the intrinsic coagulation pathway were systematized. In the 1970s, family studies in the Leiden region of the Netherlands discovered the FIX Leyden phenotype — a unique form that is severe in childhood but improves spontaneously to mild disease after puberty as FIX expression increases under the influence of testosterone — which became an important case for research on coagulation biology and hormonal regulatory mechanisms.

Advances in molecular biology and recombinant therapeutics

In 1982, Kurachi and Davie succeeded in cloning the cDNA of human FIX, and in 1985 the complete genomic structure of the F9 gene — long arm of the X chromosome at Xq27.1, total length about 34 kb, 8 exons — was fully decoded. This made it possible to identify the cause of Christmas disease at the gene level, and thousands of pathogenic variants have since been registered. In 1992, Crossley et al. showed that the molecular cause of the FIX Leyden phenotype is damage to the androgen hormone response element (AHRE) in the F9 promoter and published it in Science; this important study fully explained the mechanism of the spontaneous post-pubertal improvement in FIX Leyden. In 1998, recombinant FIX (BeneFIX, nonacog alfa) received FDA approval, opening a new era of treatment free of the risk of viral infection associated with plasma-derived products. Following the clinical success of AAV-based FIX gene therapy by Nathwani et al. in 2011, etranacogene dezaparvovec (Hemgenix), carrying the FIX Padua variant, received FDA approval in November 2022, opening the era of gene therapy for Christmas disease (hemophilia B). The name "Christmas disease" is still officially listed under ICD-10 code D67 and is used worldwide as a synonym for hemophilia B and hereditary factor IX deficiency.


2. Causes

X-linked recessive inheritance and F9 variants

Christmas disease (hemophilia B) is an X-linked recessive genetic disease caused by pathogenic variants in the F9 gene located on the long arm of the X chromosome at Xq27.1. Because males (46,XY) have only one X chromosome, the disease is expressed with just one variant allele. Females (46,XX) become carriers when only one of their two X chromosomes has a variant; most maintain normal FIX:C, but when random X inactivation (lyonization) is skewed toward the variant X chromosome, FIX:C may be significantly reduced and mild bleeding symptoms may appear. Rarely, severe hemophilia B can be expressed in females with Turner syndrome (45,X) or in homozygous/compound heterozygous females.

Variant types and frequencies

To date, thousands of pathogenic variants in the F9 gene have been registered in the HAMSTeRS database. By variant type, point mutations (missense/nonsense) account for about 84% and are the most common, with missense variants making up the majority. Small deletions account for about 8%, small insertions about 3%, large deletions about 3% and splicing variants about 2%. Whereas the representative severe variant in hemophilia A is the F8 intron 22 inversion, inversions are very rare in the F9 gene. Variants that cause severe hemophilia B commonly include premature stop codons (nonsense), frameshifts and large deletions, while mild disease is mainly caused by missense variants that partially retain function. About 30% of all patients have de novo mutations with no family history.

Vitamin K dependence and functional causes

FIX is a vitamin K-dependent serum protein synthesized in the liver. The glutamic acid residues of the Gla domain at the N-terminus of the protein are converted to gamma-carboxyglutamic acid (Gla) by vitamin K-dependent carboxylase (GGCX), and only when this process occurs normally can FIX bind to phospholipid membrane surfaces and form coagulation complexes. When an F9 gene variant is located in the Gla domain, phospholipid-binding ability may be impaired and functional activity greatly reduced even if the protein is expressed normally. Acquired reduction of FIX function due to warfarin use or vitamin K deficiency must be distinguished from hereditary Christmas disease.

FIX Leyden: a unique causative mechanism

FIX Leyden is a special subtype caused by point mutations in the F9 promoter region (-6G>A, -5G>A, -4C>T, etc.). These variants damage the androgen hormone response element (AHRE) in the F9 promoter, so that in childhood testosterone-induced F9 transcription does not occur and FIX:C is extremely low, producing a severe hemophilia B phenotype. However, after puberty, as testosterone levels rise, other regulatory pathways that bypass the damaged AHRE are activated, FIX expression gradually recovers and FIX:C rises to the mild range (5–40%), showing a course of spontaneous improvement with a marked reduction in bleeding frequency. This is a very unusual type observed only in hemophilia B and an important biological example of sex hormones regulating clotting factor expression.


3. Genetics

Basic structure of the F9 gene

The F9 gene is located on the long arm of the X chromosome at Xq27.1, has a total length of about 34 kb and consists of 8 exons (exons 1–8). The F9 gene has a much smaller and simpler structure than F8 (186 kb in total, 26 exons), the causative gene of hemophilia A, so genetic analysis is relatively easy. The mature protein FIX (factor IX) consists of 415 amino acids with a molecular weight of about 55 kDa, much smaller than FVIII (280 kDa). This size difference is also directly reflected in the plasma half-life (FIX about 18–24 hours vs FVIII about 12 hours) and in differences in treatment dosing frequency.

Protein domain structure

From the N-terminus to the C-terminus, the FIX protein consists of Gla domain - EGF1 domain - EGF2 domain - activation peptide (AP) - serine protease (SP) domain, in that order. The Gla domain (about 45 amino acids) contains 12 glutamic acid residues that are targets of the vitamin K-dependent carboxylation reaction and is essential for binding to phospholipid membranes (the surface of activated platelets) in the presence of divalent calcium ions. The EGF1 domain is mainly involved in interaction with FVIIIa and phospholipids, and the EGF2 domain contributes to binding with the substrate FX. The activation peptide (AP) is released when FIX is cleaved by FXIa or the FVIIa/tissue factor complex and activated to FIXa; because it is excreted in urine, it is sometimes used as a biochemical marker of FIX activation. The serine protease domain contains the His/Asp/Ser catalytic triad and is responsible for the enzymatic activity that cleaves the substrate FX to generate FXa.

FIX Leyden: biology of the androgen response element

FIX Leyden variants are point mutations (at several positions such as -6G>A, -5G>A, -4C>T and +13) that damage the androgen hormone response element (AHRE) in the F9 gene promoter. In a study published in Science in 1992, Crossley et al. molecularly demonstrated that variants in this region interfere with testosterone binding so that F9 transcription is suppressed in childhood, and that after puberty, as rising testosterone levels allow other transcriptional regulatory mechanisms to predominate, FIX expression recovers. This was an important study that first established hormonal regulation of clotting factor gene expression. In patients with the Leyden variant, FIX:C often recovers to 20–60% in adulthood, reaching a clinically mild or asymptomatic state.

FIX Padua: a gain-of-function variant and its application in gene therapy

The FIX Padua variant (p.Arg338Leu) is a gain-of-function variant first reported in a family from Padua, Italy, in which arginine (Arg) at position 338 in the FIX catalytic domain is replaced by leucine (Leu). This variant increases the efficiency of FX activation by the FIXa-FVIIIa complex (intrinsic tenase) to about 100 times that of normal FIX, causing a thrombotic tendency in vivo with FIX:C far exceeding the normal range. Paradoxically, this property has been applied to gene therapy: by carrying the FIX Padua variant sequence in an AAV5 vector, etranacogene dezaparvovec (Hemgenix) was designed to raise FIX:C to a therapeutically meaningful level (about 30–40% of normal) with just a single administration.

Mode of inheritance and carriers

Because Christmas disease follows an X-linked recessive mode of inheritance, the sons of carrier women have a 50% chance of being affected and the daughters a 50% chance of being carriers. About 30% of all patients arise from de novo mutations, so the diagnosis is possible even without a family history. For carrier identification, F9 gene analysis (Sanger sequencing of the 8 exons or NGS) is more accurate than FIX:C measurement, and promoter variants (when Leyden is suspected) require separate additional analysis.


4. Epidemiology

Global and national incidence

Christmas disease (hemophilia B) occurs at a frequency of 1 in 25,000–30,000 male births and accounts for about 20% of all hemophilia. It is about 4–5 times rarer than hemophilia A (1 in 5,000–10,000). According to World Federation of Hemophilia (WFH) estimates, about 160,000 people worldwide have Christmas disease, but in developing countries with weak medical infrastructure a considerable number are estimated to be undiagnosed. Korean hemophilia registry data (KBDR) report about 750 registered patients with hemophilia B, of whom about 40–50% are severe (FIX:C <1%), about 10–15% moderate (1–5%) and about 35–45% mild (5–40%).

Racial/ethnic and sex distribution

Christmas disease is not confined to any particular race or ethnicity and occurs in all ethnic groups worldwide. Because it is X-linked, it occurs overwhelmingly in males; female patients are rarely observed among those with Turner syndrome, homozygous/compound heterozygous carriers or carriers with severely skewed lyonization. Cases of the same variant concentrated in certain regional populations due to a founder effect have been reported, but overall, differences in prevalence between ethnic groups are not large.

Severity distribution and inhibitors

Severity is classified by FIX:C level. Severe: FIX:C <1 IU/dL, moderate: 1–5 IU/dL, mild: 5–40 IU/dL. The incidence of inhibitors (anti-FIX alloantibodies) is about 3–5%, markedly lower than in hemophilia A (25–30%). However, when inhibitors develop in hemophilia B, anaphylactic reactions accompany FIX infusion more often than in hemophilia A, so it can be clinically more dangerous. Inhibitors usually develop within the first 50 exposure days of FIX exposure and tend to be more frequent in severe patients.


5. Pathophysiology

Role of FIX in the intrinsic coagulation pathway

Blood coagulation is divided into the extrinsic pathway (tissue factor pathway) and the intrinsic pathway (contact activation pathway), and FIX plays a key role mainly in the intrinsic pathway. When the intrinsic pathway is activated after vascular injury, FXIIa activates FXIa, and FXIa activates FIX to FIXa in the presence of Ca²⁺. The FVIIa-tissue factor (TF) complex of the extrinsic pathway can also directly activate FIX, so FIX also contributes to the sustained coagulation amplification phase after initiation of the extrinsic pathway. In this way, FIX occupies a strategic position involved in amplifying thrombin generation in both the intrinsic and extrinsic pathways.

Formation of the intrinsic tenase complex and FX activation

FIXa alone activates FX very inefficiently. When FIXa forms the intrinsic tenase complex (intrinsic Xase/tenase complex) together with the cofactor protein FVIIIa, divalent calcium ions (Ca²⁺) and a negatively charged phospholipid membrane (the surface of activated platelets), the efficiency of FX activation increases by about 100,000-fold (10⁵-fold) or more. In this complex, FIXa plays the catalytic role and FVIIIa acts as the cofactor. When FX is activated to FXa by intrinsic tenase, FXa forms the prothrombinase complex of the common pathway (FXa-FVa-Ca²⁺-phospholipid) and converts large amounts of prothrombin to thrombin. Thrombin converts fibrinogen to fibrin and further activates platelets to form a stable clot.

Pathophysiology of FIX deficiency and hemostatic failure

When FIX is deficient, the intrinsic tenase complex cannot form, so FXa generation is extremely limited. The FVIIa-TF complex of the extrinsic pathway can transiently activate FX and contribute to initial hemostatic plug formation, but this pathway is rapidly inhibited by tissue factor pathway inhibitor (TFPI). Therefore, in FIX deficiency, even if initial hemostasis is possible, not enough thrombin is generated to form a sustained, stable fibrin clot, so clots are unstable or rebleeding occurs. This is the fundamental reason why hemostasis is delayed even after minor trauma and spontaneous bleeding occurs in Christmas disease.

Development of hemophilic arthropathy

In patients with severe Christmas disease, repeated intra-articular bleeding (hemarthrosis) causes chronic inflammation of synovial tissue, iron ions aggravate oxidative damage, and this eventually progresses to hemophilic arthropathy, leading to synovial thickening, cartilage destruction and joint fibrosis. This process unfolds over years to decades, and if bleeding frequency is not suppressed by early prophylaxis, permanent damage to joint function occurs.


6. Symptoms

Severe (FIX:C < 1 IU/dL)

In patients with severe Christmas disease, spontaneous bleeding recurs without any obvious trauma. The most common and characteristic symptom is spontaneous hemarthrosis, which occurs mainly in large joints such as the knees, ankles and elbows and is accompanied by pain, warmth, swelling and limited range of motion due to blood accumulation in the joint. Repeated hemarthrosis progresses to hemophilic arthropathy, causing permanent joint deformity and functional impairment. Muscle hematomas also occur frequently in severe patients; in particular, iliopsoas hematoma can cause femoral neuropathy due to femoral nerve compression and requires immediate treatment. Intracranial hemorrhage is the most serious complication in patients with severe hemophilia and a major cause of death or permanent neurological damage. In the neonatal period, the disease is sometimes first detected through excessive bleeding from birth trauma, neonatal circumcision or blood sampling sites.

Moderate (FIX:C 1–5 IU/dL)

Moderate patients show a tendency toward excessive bleeding after minor trauma or procedures rather than spontaneous bleeding. Joint bleeds also occur but are less frequent than in severe disease and appear mainly after trauma. Hemostasis may be delayed after surgery or dental procedures, and muscle hematomas may develop even from relatively light contact. If diagnosis is delayed, patients sometimes experience dangerous bleeding complications during or after surgery.

Mild (FIX:C 5–40 IU/dL) and adult onset

Mild patients often have no bleeding symptoms in daily activities, and abnormal bleeding may first be identified in specific situations such as surgery, tooth extraction, childbirth or severe trauma. For this reason, not a few cases go undiagnosed until adulthood and are first diagnosed because of excessive bleeding during surgery or after dental procedures. Patients with the FIX Leyden variant show a unique course in which they have a severe phenotype in childhood, but after puberty FIX:C rises spontaneously to the mild range and bleeding frequency decreases markedly in adulthood. After reaching adulthood, they are effectively managed as having mild hemophilia B.


7. Signs

Coagulation test findings

The most characteristic laboratory finding in Christmas disease is isolated prolongation of the activated partial thromboplastin time (APTT). Prothrombin time (PT/INR), thrombin time (TT), fibrinogen level, platelet count and bleeding time all remain within the normal range. The degree of APTT prolongation is inversely proportional to the FIX:C level, and the more severe the disease, the more the APTT is prolonged. However, in mild patients the APTT may fall within the normal range, so if clinically suspected, FIX:C must be measured directly regardless of the APTT. FIX:C is measured by the one-stage clotting assay (OSA) or the chromogenic assay (CSA); because discrepancies between the two methods can occur with some variants, such as Gla domain variants, comparing the results of both is recommended.

Inhibitor test findings

In patients treated with FIX concentrates, the development of inhibitors (anti-FIX alloantibodies) should be suspected when treatment response is poor or bleeding is difficult to control. Inhibitors are quantified in Bethesda Units (BU) and classified as high titer (≥5 BU/mL) or low titer (<5 BU/mL). The incidence of inhibitors in Christmas disease is about 3–5%, much lower than in hemophilia A (25–30%). However, when inhibitors develop in Christmas disease, it is clinically especially dangerous because anaphylactic reactions (acute hypersensitivity reactions) are more likely to accompany FIX infusion than in hemophilia A. The risk of inhibitors and anaphylaxis is known to be higher in severe patients with large deletions.

Joint and imaging findings

In joints with repeated hemarthrosis, plain radiographs show findings of hemophilic arthropathy such as joint space narrowing, bone erosion, cystic changes and joint deformity. Early soft tissue changes such as synovial thickening and joint effusion can be assessed more sensitively with ultrasound or MRI. Muscle hematomas can be diagnosed early with ultrasound, and intracranial hemorrhage is confirmed with CT or MRI. When intracranial hemorrhage is suspected, administration of FIX concentrate must be started without delay at the same time as emergency imaging.


8. Screening

Screening of newborns with a family history

When there is a family history of Christmas disease, early FIX:C testing in newborns is recommended. However, FIX:C in the neonatal period is measured lower than the adult normal range even in normal newborns, so careful attention is needed in interpreting the results. FIX:C in term newborns is low, at about 15–50% of adult normal values (50–150 IU/dL), and is even lower in the early neonatal period. Because of this physiological characteristic, it may be difficult to confirm hemophilia B immediately even if FIX:C is measured low in the neonatal period, and retesting after 6 months of age is recommended. If there is clinical bleeding or severe or moderate hemophilia B is strongly suspected, treatment can be started under a provisional diagnosis even in the neonatal period.

Screening and differentiation when APTT is prolonged

When the APTT is prolonged on blood tests performed for other reasons and the PT, platelet count and fibrinogen are normal, intrinsic pathway factor deficiency or the presence of an inhibitor must be differentiated. Intrinsic pathway factors including FIX:C, FVIII:C, FXI:C and FXII:C are measured sequentially, and whether the APTT is corrected on a mixing test (1:1 mix) is checked to differentiate factor deficiency from an inhibitor. A specific reduction in FIX:C strongly suggests Christmas disease.

Carrier screening and testing of female family members

Determining carrier status in female family members such as the patient's mother, sisters and daughters is essential for genetic counseling and family planning. Because FIX:C measurement alone has low sensitivity for carrier identification, F9 gene analysis (Sanger sequencing or NGS) is recommended as the first choice. Identified carrier women must have FIX:C measured before surgery, procedures or childbirth, and if FIX:C is 40 IU/dL or below, a plan for bleeding prevention measures must be established.


9. Diagnosis

Diagnostic algorithm

The definitive diagnosis of Christmas disease is made by a stepwise approach. The first step is confirmation of a prolonged APTT. If the APTT is prolonged and the PT, TT, platelets and fibrinogen are normal, an intrinsic pathway abnormality is suspected. The second step is quantification of FIX:C. The one-stage clotting assay is the standard method, and the chromogenic assay is used complementarily. Because discrepancies between the two methods can occur with some variants (especially Gla domain missense variants), comparing the results of both methods is recommended. If FIX:C is reduced, the third step is a mixing test and inhibitor testing to differentiate factor deficiency from an inhibitor.

Genetic analysis and confirmation

F9 gene analysis is recommended for confirmation and genetic counseling. Sanger sequencing of all 8 exons and intron-exon junctions or hemophilia panel NGS is used. If no variant is found in the coding region, additional analysis of the promoter region (especially important when FIX Leyden is suspected), 5'UTR and 3'UTR is needed. Large deletions or duplications are confirmed by array CGH or MLPA. The results of genetic analysis are used directly for predicting severity, assessing the risk of inhibitor development, genetic counseling and prenatal diagnosis. When FIX Leyden is suspected (a course that is severe in childhood and improves spontaneously after puberty), F9 promoter region analysis must be included.

Differential diagnosis

Differentiation from diseases showing isolated APTT prolongation is necessary. The main conditions to differentiate are hemophilia A (reduced FVIII:C, normal FIX:C), factor XI deficiency (hemophilia C, autosomal recessive, common in Ashkenazi Jews), factor XII deficiency (no clinical bleeding), von Willebrand disease type 2N (accompanied by reduced FVIII:C but no reduction in VWF antigen) and lupus anticoagulant (not corrected on mixing test). Differentiation is possible by quantification of each factor and mixing tests.


10. Treatment

FIX concentrates: standard half-life

The standard treatment for Christmas disease is administration of FIX concentrates. Both plasma-derived (pdFIX) products and recombinant (rFIX) standard half-life products are available. Recombinant standard half-life products include BeneFIX (nonacog alfa) and Rixubis (nonacog gamma). The plasma half-life of FIX is about 18–24 hours, longer than that of FVIII (about 12 hours), so during prophylaxis, dosing 1–2 times a week can maintain sufficient trough levels. Both on-demand treatment of bleeding episodes and prophylaxis to prevent spontaneous bleeding are used. High-dose administration aiming for FIX:C of 100% before surgery and postoperative FIX:C maintenance therapy are also included.

Extended half-life (EHL) FIX products

EHL products greatly extend the half-life by applying Fc fusion, albumin fusion or PEGylation technology to recombinant FIX. Alprolix (eftrenonacog alfa, FIX-Fc fusion): half-life about 82 hours, administered once weekly or once every 2 weeks. Idelvion (albutrepenonacog alfa, FIX-albumin fusion): half-life about 104 hours, administered every 2 weeks or once every 4 weeks. Rebinyn (nonacog beta pegol, PEG-FIX): half-life about 93 hours, administered once weekly. EHL products reduce the number of injections, improving patients' treatment adherence and quality of daily life, and are particularly advantageous in reducing the number of venous accesses in pediatric patients.

Non-factor therapies: emicizumab and fitusiran

Emicizumab (Hemlibra) is a bispecific antibody that binds FIXa and FX simultaneously, replacing FVIIIa-like function to restore intrinsic tenase function. It was originally developed for the hemophilia A indication, but because the FIXa-FX bridging function also works in hemophilia B patients with inhibitors, its use in hemophilia B is expanding. It can be given by subcutaneous injection once weekly, once every 2 weeks or once every 4 weeks. Fitusiran is an RNAi therapeutic targeting antithrombin that increases thrombin generation by suppressing antithrombin. It can be used in both hemophilia A and B regardless of the presence of inhibitors and is given by subcutaneous injection once a month.

Gene therapy: etranacogene dezaparvovec (Hemgenix)

Etranacogene dezaparvovec (Hemgenix, AMT-061, CSL Behring), approved by the FDA in November 2022, is a gene therapy that carries a hepatocyte-specific hybrid promoter (ApoE-hAAT) and the FIX Padua variant (p.Arg338Leu) sequence in an AAV5 vector. A single intravenous administration in adult patients with severe or moderate Christmas disease leads to sustained expression of FIX Padua in hepatocytes, maintaining FIX:C at about 30–40% of normal and greatly reducing bleeding episodes. This effect was demonstrated in a phase 3 clinical trial (HOPE-B); because liver enzyme elevation may occur within weeks after administration, prophylactic steroid administration and monitoring are needed. Follow-up of long-term efficacy and safety is ongoing.

Inhibitor management

When inhibitors develop in Christmas disease, FIX concentrates are rendered ineffective, so bleeding is controlled with bypassing agents (aPCC: activated prothrombin complex concentrate, or recombinant FVIIa/NovoSeven). Immune tolerance induction (ITI) has a success rate of 70–80% in hemophilia A, but in Christmas disease the success rate is low at about 30–40% and is accompanied by a risk of anaphylaxis with FIX infusion, so it is difficult to recommend actively. Therefore, in patients with Christmas disease who have inhibitors, switching to emicizumab is currently the most preferred treatment strategy.


11. Prognosis

Modern treatment and life expectancy

When there were no treatment options, the life expectancy of patients with severe Christmas disease was so short that they rarely lived past their teens. Survival improved dramatically with the successive introduction of cryoprecipitate, FIX concentrates and recombinant products. There was the tragedy of the contaminated blood scandals of the 1980s–90s (mass HIV and HCV infections in Canada and several other countries), but since 1998 this risk has almost disappeared with the introduction of recombinant products. The life expectancy of patients with Christmas disease receiving modern prophylaxis has improved to a level almost equal to that of normal males. Minimizing the frequency of hemarthrosis with early prophylaxis also largely prevents hemophilic arthropathy, greatly improving quality of life.

Inhibitors and long-term prognosis

The incidence of inhibitors in Christmas disease is about 3–5%, markedly lower than in hemophilia A (25–30%), so the overall prognosis is better. When inhibitors develop, re-administration of FIX may be difficult because of the risk of anaphylaxis, but bleeding can be controlled by switching to emicizumab. Patients with the FIX Leyden variant shift to the mild range in adulthood owing to spontaneous improvement after puberty, so the long-term prognosis is even better in this subtype. The long-term prognosis in patients who have received gene therapy is currently under follow-up, and AAV loss due to hepatocyte division, immune responses and liver enzyme elevation remain variables that may affect long-term efficacy.

Joint health and quality of life

Most severe patients in the era before early prophylaxis began suffered severe hemophilic arthropathy. Currently, by maintaining high FIX trough levels with EHL products or non-factor therapies to minimize the frequency of spontaneous bleeding, the long-term prognosis for joint health is improving greatly. Adult patients whose joint damage has already progressed sometimes need joint replacement surgery, and sufficient perioperative FIX replacement and thorough management by a specialized hemophilia team are the key factors determining the surgical outcome.


12. Prevention

Genetic counseling and carrier identification

Because Christmas disease is an X-linked recessive genetic disease, systematic genetic counseling for the patient's family is essential. Carrier status in female family members such as the patient's mother, sisters and daughters must be determined by F9 gene analysis (NGS or Sanger sequencing). Because FIX:C measurement alone has low sensitivity for carrier identification, genetic analysis takes priority. Carrier women should have FIX:C monitored periodically, must have FIX:C checked before childbirth, surgery or invasive procedures, and should plan prophylactic FIX replacement if needed. Some carrier women with severely skewed lyonization have a bleeding risk at the level of mild hemophilia B, so clinical caution is needed.

Prenatal diagnosis and preimplantation genetic testing

When a carrier woman becomes pregnant, prenatal genetic diagnosis of the fetus can be offered. Chorionic villus sampling (CVS) is performed at 10–13 weeks of pregnancy, and hemophilia B can be determined by F9 gene analysis of fetal cells. Amniocentesis is performed at 15–20 weeks of pregnancy. Preimplantation genetic testing (PGT) is a method in which embryos are tested for the F9 variant before embryo transfer during in vitro fertilization (IVF) and only normal or carrier embryos are selectively transferred; it is an alternative that can prevent the birth of a child with Christmas disease without termination of pregnancy. All prenatal diagnosis and PGT options should be offered together with thorough genetic counseling.

Early prophylaxis

In patients with severe Christmas disease, early prophylaxis is the most reliable means of preventing hemophilic arthropathy. International hemophilia guidelines recommend starting prophylaxis before the first joint bleed or before age 2. Standard FIX concentrates can be given 1–2 times a week, and EHL products (Alprolix, Idelvion, etc.) every 2 weeks or once every 4 weeks, reducing the burden of venous access in pediatric patients. The expansion of indications for subcutaneous formulations such as emicizumab to Christmas disease is further increasing the convenience of early prophylaxis. The goal of prophylaxis is to maintain FIX trough levels at or above 1–3 IU/dL to prevent spontaneous bleeding, and ideally, intensified prophylaxis targeting higher trough levels (e.g., 5 IU/dL or above) is sometimes recommended.

Lifestyle management and bleeding prevention

Daily management that minimizes bleeding risk is important for patients with Christmas disease. Drugs that inhibit platelet function, such as aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), are avoided; subcutaneous or intravenous injections are used and intramuscular injections are avoided as much as possible. Before surgery, tooth extraction or procedures, a plan for prophylactic FIX administration must always be established in advance in consultation with the specialized hemophilia team. Regular exercise helps strengthen the muscles around joints and maintain joint health, so low-impact exercise such as swimming and cycling is recommended, while contact sports such as martial arts and rugby or activities with a high risk of trauma are restricted. Maintaining a long-term follow-up relationship with a specialized hemophilia treatment center is essential for optimal clinical outcomes.


13. References

  1. Biggs R, Douglas AS, Macfarlane RG, et al. Christmas disease: a condition previously mistaken for haemophilia. BMJ. 1952;2(4799):1378-1382.
  2. Schulman I, Smith CH. Hemorrhagic disease in an infant due to deficiency of a previously undescribed clotting factor. Blood. 1952;7(8):794-807.
  3. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA. 1982;79(21):6461-6464.
  4. Crossley M, Ludwig M, Stowell KM, et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science. 1992;257(5068):377-379.
  5. Pipe SW, Leebeek FW, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706-718.
  6. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Haemophilia, 3rd edition. Haemophilia. 2020;26(S6):1-158.
  7. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19(5):876-885.
  8. Mahlangu J, Iorio A, Kenet G, et al. Fitusiran prophylaxis in patients with haemophilia A or B. N Engl J Med. 2023;389(20):1843-1855.
  9. Oldenburg J, Pavlova A. Inhibitors in haemophilia B: a review. Haemophilia. 2014;20 Suppl 4:41-47.
  10. Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.